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ABSTRACT
Although respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants, a safe and effective
vaccine is not yet available. Live-attenuated vaccines (LAVs) are the most advanced vaccine candidates in RSV-naive infants.
However, designing an LAVwith appropriate attenuation yet sufficient immunogenicity has proven challenging. In this study,
we implemented reverse genetics to address these obstacles with a multifaceted LAV design that combined the codon deoptimi-
zation of genes for nonstructural proteins NS1 and NS2 (dNS), deletion of the small hydrophobic protein (SH) gene, and re-
placement of the wild-type fusion (F) protein gene with a low-fusion RSV subgroup B F consensus sequence of the Buenos Aires
clade (BAF). This vaccine candidate, RSV-A2-dNS-SH-BAF (DB1), was attenuated in twomodels of primary human airway
epithelial cells and in the upper and lower airways of cotton rats. DB1 was also highly immunogenic in cotton rats and elicited
broadly neutralizing antibodies against a diverse panel of recombinant RSV strains. When vaccinated cotton rats were chal-
lenged with wild-type RSV A, DB1 reduced viral titers in the upper and lower airways by 3.8 log10 total PFU and 2.7 log10 PFU/g
of tissue, respectively, compared to those in unvaccinated animals (P< 0.0001). DB1 was thus attenuated, highly immunogenic,
and protective against RSV challenge in cotton rats. DB1 is the first RSV LAV to incorporate a low-fusion F protein as a strategy
to attenuate viral replication and preserve immunogenicity.
IMPORTANCE
RSV is a leading cause of infant hospitalizations and deaths. The development of an effective vaccine for this high-risk popula-
tion is therefore a public health priority. Although live-attenuated vaccines have been safely administered to RSV-naive infants,
strategies to balance vaccine attenuation with immunogenicity have been elusive. In this study, we introduced a novel strategy to
attenuate a recombinant RSV vaccine by incorporating a low-fusion, subgroup B F protein in the genetic background of codon-
deoptimized nonstructural protein genes and a deleted small hydrophobic protein gene. The resultant vaccine candidate, DB1,
was attenuated, highly immunogenic, and protective against RSV challenge in cotton rats.
Respiratory syncytial virus (RSV) is the leading cause of lowerrespiratory tract infections in infants (1). Globally, RSV causes
an estimated 3.4 million (1) hospitalizations and 234,000 deaths
per year in children under the age of 5 years (2). Almost all chil-
dren have been infected with RSV by the age of 2 years, with
clinicalmanifestations ranging fromupper respiratory tract infec-
tions to pneumonia with respiratory failure. Despite the striking
burden of RSV disease in children worldwide, no RSV-specific
therapies or vaccines are commercially available. The develop-
ment of a safe and effective RSV vaccine is therefore a public
health priority.
The initial attempt to develop an RSV vaccine by formalin
inactivation (FI-RSV) not only failed to protect against infection
but also primed RSV-naive infants for enhanced respiratory dis-
ease upon natural infection (3). Subsequent animal studies also
demonstrated enhanced disease following vaccination with some
RSV protein-based vaccines (4, 5). Although many protein-based
vaccines have not caused enhanced disease in animals, the risk of
this outcome has hindered their administration to seronegative
infants to date. In contrast, RSV live-attenuated vaccines (LAVs)
have never been associated with enhanced disease in animal mod-
els or in humans (6). Thus, LAVs are the only RSV vaccines which
have been safely administered to the target population of RSV-
naive infants. LAVs offer multiple advantages over nonreplicating
vaccines, including intranasal administration and the ability to
broadly stimulate cellular and humoral immune responses. How-
ever, one major limitation of LAVs is the relatively poor immu-
nogenicity and incomplete protection conferred by natural
RSV infection. A successful LAVmust therefore maintain its im-
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munogenicity yet be sufficiently attenuated so as not to cause
symptoms in recipients.
RSV reverse genetics has enabled the rational design of LAVs
which incorporate genetic modifications designed to balance at-
tenuation and immunogenicity. One such genetic modification
we recently described is the codon deoptimization of RSV non-
structural proteins NS1 and NS2 (dNS), which are virulence pro-
teins that antagonize the host interferon responses (7). Codon
deoptimization (8, 9) and codon pair deoptimization (10, 11) are
strategies to decrease viral protein expression by incorporating the
least used codons or least used codon pairs in the human genome,
respectively. In previous studies, deletion of NS1 was overattenu-
ating in nonhuman primates (12), whereas deletion of NS2 was
underattenuating (13). However, we demonstrated that codon
deoptimization reduced expression of NS1 andNS2 by 70 to 90%,
which resulted in an LAV that was moderately attenuated in vivo,
with enhanced immunogenicity inmice compared to that of wild-
type virus (7). Similarly, the deletion of the small hydrophobic
(SH) protein has been introduced into multiple RSV LAV candi-
dates because of its potential to attenuate site-specific viral repli-
cation in vivo (13, 14) without compromising immunogenicity
(14). Importantly, the codon deoptimization of nonstructural
proteins and the deletion of SH do not attenuate viral replication
in Vero cells, which could allow for LAV production in this cell
line (7, 14, 15).
In this study, our objective was to implement reverse genetics
to design an RSV LAV which was both attenuated and immuno-
genic. To accomplish this, we first identified an RSV subgroup B F
protein consensus sequence of the Buenos Aires clade (BAF) with
poor fusogenicity compared to that of wild-type F protein. We
then incorporated BAF into the genetic background of RSV-A2
with codon-deoptimized nonstructural protein genes and a dele-
tion of the small hydrophobic protein gene. The resultant vaccine
candidate, RSV-A2-dNS-SH-BAF (DB1), was attenuated, highly
immunogenic, and protective against RSV A challenge in cotton
rats. Additionally, DB1 elicited broadly neutralizing antibodies
against a novel panel of recombinant reporter viruses representing
diverse RSV A and B subgroup isolates.
MATERIALS AND METHODS
Cell lines and primary cell cultures. HEp-2 (ATCC CCL-23), Vero
(ATCC CCL-81), and 293T (ATCC, CRL-3216) cells were maintained in
minimal essential medium (MEM) with Earle’s salts and L-glutamine
(Gibco) supplemented with 10% fetal bovine serum (FBS; HyClone) and
1 g/ml of penicillin, streptomycin sulfate, and amphotericin B solution
(PSA; Life Technologies, Grand Island, NY). BEAS-2B cells were main-
tained in RPMI 1640 (Cellgro) with 10% FBS and 1 g/ml of PSA as
described previously (16). BSR T7/5 cells (a gift from Ursula Buchholz,
National Institutes of Health, Bethesda, MD) were cultured in Glasgow’s
minimal essential medium (GMEM) containing 10% FBS, 1 g/ml of
PSA, and, every other passage, Geneticin at 1 mg/ml as described previ-
ously (17).
Normal human bronchial epithelial (NHBE) cells (Lonza, Allendale,
NJ) were cultured at the air-liquid interface (ALI) according to the rec-
ommended protocols as described previously (7). Human airway epithe-
lial (HAE) cells were isolated from airway specimens of patients without
underlying lung disease by the University of North Carolina (UNC)Mar-
sico Lung Institute TissueCultureCore, which obtained airway specimens
with informed consent under UNC at Chapel Hill Institutional Review
Board-approved protocols from the National Disease Research Inter-
change (NDRI; Philadelphia, PA). Primary cells were expanded on plastic
for one passage and plated at a density of 3 105 per well on permeable
Transwell-Col supports. HAE cell cultures were grown at an ALI for 4 to
6 weeks to form differentiated, polarized cultures, as described previ-
ously (18).
Cloning and rescue of recombinant viruses. To generate the BAF
consensus sequence, the full-length F gene nucleotide sequences from 5
BA isolates deposited under GenBank accession numbers JF714712,
JN032115, JN032117, JN032119, and JN032120 were obtained (http:
//www.ncbi.nlm.nih.gov/GenBank/index.html). These sequences were
aligned using MegAlign within the DNASTAR, Inc., Lasergene Suite
(Madison, WI), and the consensus BAF gene was synthesized by GeneArt
(Thermo Fisher Scientific, Inc., Waltham, MA).
We next generated recombinant viruses kRSV-A2, kRSV-A2-line19F,
kRSV-A2-BAF, kRSV-A2-dNS-SH-BAF (kDB1), and RSV-A2-dNS-
SH-BAF (DB1) and a panel of viruses expressing mKate2 and the G and
F surface glycoproteins of diverse RSV clinical isolates within an A2 back-
bone using reverse genetics as previously described (17). To do this, we
mademodifications to the pSynkRSV-line19F bacterial artificial chromo-
some (BAC), which contains the antigenome of kRSV-A2-line19F un-
der the control of a T7 promoter with far-red fluorescent protein
monomeric Katushka-2 (mKate2) in the first gene position to facilitate
virus detection and quantification (17). We previously described mod-
ifications of pSynkRSV-A2-line19F to yield pSynkRSV-A2 and pSyn-
kRSV-A2-dNS, which produce kRSV-A2 and kRSV-A2-dNS, respec-
tively, where dNS represents complete codon deoptimization of NS1 and
NS2 incorporating the least used codons in humans (7). To generate
kRSV-A2-BAF, we cloned the BAF gene into pSynkRSV-A2 using SacII
and SalI restriction sites.
To generate kDB1, we first removed the SH gene from pSynkRSV-A2-
dNS using recombination-mediated mutagenesis (recombineering) with
positive and negative selection of the galactokinase expression cassette
(galK) as previously described (17, 19). To generate the galK casette, the
following oligonucleotides were synthesized (Integrated DNA Technolo-
gies, Coralville, IA): dSH50f (5=-AGATCTAGTACTCAAATAAGTT
AATAAAAAATATACACATGGACGTCCATCCTGTTGACAATTA
ATCATCGGCA-3=) and dSH50r (5=-GTCTTAGCGGTGCGTT
GGTCCTTGTTTTTGGACATGTTTGCATTTGCCCCTCAGCACT
GTCCTGCTCCTT-3=). We then amplified the sequence using PCR to
generate the galK cassette flanked by RSV homology arms. Upon recom-
bination, the galK cassette replaced the SH sequence to be deleted. For the
second recombination step, to replace the galK cassette with the desired
SH deletion, we used annealed oligonucleotide adapters with the follow-
ing sequences: dSH100f (5=-AGATCTAGTACTCAAATAAGTTAATAAA
AAATATACACATGGACGTCCATGGGGCAAATGCAAACATGTCCAA
AAACAAGGACCAACGCACCGCTAAGAC-3=) and dSH100r (5=-GT
CTTAGCGGTGCGTTGGTCCTTGTTTTTGGACATGTTTGCA
TTTGCCCCATGGACGTCCATGTGTATATTTTTTATTAACTT
ATTTGAGTACTAGATCT-3=). Following recombineering, the deletion
of the SH gene from pSynkRSV-A2-dNS was confirmed by sequencing.
We then used SacII-SalI restriction sites to clone the synthetic BAF
sequence in place of the A2F sequence to generate pSynkRSV-A2-dNS-
SH-BAF, which produced kDB1. A version of DB1 without the mKate2
gene was also generated from pSynkRSV-dNS-SH-BAF by excising the
coding region containing the mKate2 gene with KpnI and AvrII. The
resultant fragment containing mKate2 flanked by identical BlpI sites was
then excised using BlpI, and the flanking fragments were ligated to gen-
erate pSynkRSV-dNS-SH-BAF without mKate2.
To construct the panel of recombinant viruses expressing mKate2
and clinical G and F surface glycoproteins within an A2 backbone, we
selected 6 distinct RSV clinical strains with published G and F nucle-
otide sequences representing both A and B subgroups isolated from
diverse temporal and geographic settings. The strains included (Gen-
Bank numbers are in parentheses) RSV A strains RSVA/human/USA/
A1998-12-21 (JX069802), A/2001/2-20 (JF279545 and JF279544), Riyadh
91/2009 (JF714706 and JF714710), and RSVB strains NH1276 (JQ680988
and JQ736678), 9320 (AY353550), and TX11-56 (JQ680989 and
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JQ736679). We obtained the synthetic G and F nucleotide sequences of
these clinical isolates, flanked by SacI-SacII and SacII-SalI restriction sites,
respectively. We used these restriction sites to clone the corresponding G
and F genes into pSynkRSV-A2-line19F. We also generated a recombi-
nant RSV strainwithoutGprotein expression (kRSV-A2-220F-G-stop) as
previously described (20, 21).
We recovered all recombinant viruses by cotransfecting the RSV anti-
genomic BACs with four human codon-optimized helper plasmids that
expressed RSV N, P, M2-1, or L protein into BSR T7/5 cells (17). Master
and working virus stocks of vaccine strains were subsequently propagated
and harvested in Vero cells (7). The panel of viruses expressing clinical
G and F surface glycoproteins was propagated and harvested in HEp2
cells. For cotton rat studies, RSVA/Tracy and RSVB/18537 stocks were
generated in HEp-2 cells as previously described (22).
DSP fusion assay. A dual-split-protein (DSP) cell-to-cell fusion assay
was used to quantify fusion activity of expressed RSV F proteins as de-
scribed previously (23–25). The consensus BAF gene was obtained in
mammalian codon optimized form from GeneArt and cloned into
pcDNA3.1. Subconfluent 293T cells in 12-well plates were transfected
using Lipofectamine 2000 (ThermoFisher Scientific,Waltham,MA).One
population of cells was transfected with DSP1-7 and a plasmid encoding
the RSV F protein of interest (BAF, A2F, or line19F, all codon optimized),
while another population of cells was transfected with DSP8-11. All plas-
midswere transfected at a concentration of 1g perwell in the presence of
the fusion inhibitor BMS-433771 (provided by Jin Hong, Alios Biop-
harma, San Francisco, CA) (26). Twenty-four hours posttransfection,
cells were resuspended, mixed at a 1:1 ratio, and supplemented with
EnduRen live-cell luciferase substrate (Promega, Madison, WI) at 34
g/ml in a 96-well opaque plate.Mixed cells weremaintained at 37°C, and
luciferase activity was quantified using a TopCount NXTmicroplate scin-
tillation and luminescence counter (PerkinElmer, Waltham, MA) at the
indicated time points.
In vitro growth analyses. Subconfluent BEAS-2B cells in 6-well plates
were infected in triplicate with either kRSV-A2 or kRSV-BAF at a multi-
plicity of infection (MOI) of 0.01 fluorescent focus unit (FFU)/cell in a
volume of 500 l. After rocking at room temperature for 1 h, the inocu-
lum was removed, the cells were washed with phosphate-buffered saline
(PBS), 2 ml of complete growth medium was added to each well, and
plates were incubated at 37°C in 5% CO2. Then, at specified time points
postinfection (p.i.), cells were scraped into medium and aliquots were
stored at80°C until analysis.
Titrations were performed by FFU assay as previously described (7),
with slight modifications. Briefly, HEp-2 cells at 70% confluence in 96-
well plates were inoculated in duplicate with 50 l of 10-fold serial dilu-
tions of samples. Plates were spinoculated at 2,095 g for 30 min at 4°C,
and 0.75% methylcellulose (EMD, Gibbstown, NJ) dissolved in MEM
supplemented with 10% FBS and 1% PSA was added. Cells were incu-
bated for 48 h at 37°C in 5% CO2 before counting of FFU per well. The
limit of detection was defined as 2 FFU per well, corresponding to 40
FFU/ml.
Similarly, subconfluent Vero cells in 6-well plates were infected in
triplicate with kRSV-A2-line19F or kDB1 at an MOI of 0.01 FFU/cell.
Following the above-described protocol, cells were scraped into medium
at specified time points p.i. and aliquots were stored at80°C until titra-
tion by FFU assay.
Differentiated NHBE cells from two donors were infected at an MOI
of 2.6 FFU/cell. Virus inoculum (100 l) was applied apically after PBS
wash, and samples were incubated for 2 h at 37°C. The inoculumwas then
removed by three apical PBS washes. To collect virus for specified time
points p.i., differentiatedmediumwithout an inducer (150l) was added
to the apical chamber and incubated for 10 min at 37°C. This step was
repeated twice for each well (300l total), and the apical supernatant was
snap-frozen in liquid nitrogen and stored at80°C until analysis (7).
HAE cells from two donors were infected with an MOI of 6.0 50%
tissue culture infective doses (TCID50)/cell after washing the apical sur-
faces with PBS and supplying fresh medium to the basolateral compart-
ments. Cells were incubated for 2 h at 37°C. The inoculum was then
removed, and cells were washed three times for 5 min each with PBS and
incubated at 37°C. Virus released into the apical compartment was har-
vested by performing apical washes with 425 l of medium for 30 min at
37°C. Samples were collected on days 1 to 7 p.i. and stored at80°C until
analysis (18).
Western blotting. BEAS-2B cells at 70% confluence were infected
with kRSV-A2line19F or kDB1 at an MOI of 1 FFU/cell or were mock
infected. Cell lysates were harvested at 24 h p.i. in radioimmunoprecipi-
tation assay (RIPA) buffer (Sigma-Aldrich, St. Louis, MO) and were
cleared by centrifugation at 12,000 g for 5 min. Proteins were separated
by SDS-PAGE and were transferred to polyvinylidene fluoride (PVDF)
membranes.Western blot analyses were performed by sequential probing
with polyclonal rabbit antisera against NS1 and NS2 (gifts from Michael
Teng, USF Health), motavizumab (anti-RSV F; provided by Nancy Ul-
brandt, MedImmune), or D14 (anti-RSV N; a gift from Edward Walsh,
University of Rochester) as a loading control, followed by the appropriate
peroxidase-conjugated anti-rabbit, anti-human, or anti-mouse second-
ary antibodies (Jackson ImmunoResearch, West Grove, PA). The chemi-
luminescent signal was developed using Western Bright Quantum sub-
strate (Advansta, Menlo Park, CA) and detected on a ChemiDoc XRS
analyzer (Bio-Rad, Hercules, CA). Antibodies were stripped from mem-
branes using RestoreWestern protein stripping buffer (Thermo Scientific
Inc., Waltham, MA) and reprobed.
Animals. Inbred Sigmodon hispidus cotton rats were obtained from
colonies maintained at Sigmovir Biosystems, Inc. (Rockville, MD) for
kA2-BAF and histopathology experiments or Baylor College of Medicine
(Houston, TX) for DB1 experiments. Four- to 8-week-old animals were
used for all experiments. Animals were housed in large polycarbonate
cages andwere fed a standard diet of rodent chow andwater ad libitum. All
studies were conducted under applicable laws and guidelines and after
approval from the Sigmovir Biosystems, Inc., or Baylor College of Medi-
cine Institutional Animal Care and Use Committee, respectively.
Viral attenuation in cotton rats. Cotton rats (5 per group) were
lightly anesthetized with isoflurane and inoculated intranasally (i.n.) with
105 FFU of either kRSV-A2-line19F or kRSV-A2-BAF. Following CO2
euthanasia on day 4 p.i., the left lobe of the lung was homogenized in 1ml
of Hanks balanced salt solution (HBSS) plus 10% sucrose-phosphate-
glutamate plus 1% amphotericin B (Fungizone) plus 0.1% gentamicin for
determination of lung viral titers as previously described (27).
To measure lung lavage and nasal wash titers of viruses kRSV-A2 and
kDB1, groups of 3 cotton rats were similarly inoculated i.n. with 105 PFU
of virus. On day 4 p.i., animals were sacrificed and nasal washes and lung
lavages were performed. For nasal washes, the jaws were disarticulated,
the head was removed, and 1 ml of Iscove’s medium with 15% glycerin
mixed with 2% FBS-MEM (1:1, vol/vol) was pushed through each naris
(total of 2 ml). For lung lavages, the left lung and one of the large lobes of
the right lung were removed and rinsed in sterile water to remove external
blood contamination. The lung lobes were transpleurally lavaged using 3
ml of Iscove’s medium with 15% glycerin mixed with 2% FBS-MEM.
Fluid was collected and stored on ice until analysis. Viral titration of these
specimens was performed by standard plaque assays using 24-well tissue
culture plates as described previously (22). The plaques in wells contain-
ing between 20 and 100 plaques were enumerated, the average was ob-
tained, and virus titers were calculated as the total log10 number of PFU
for nasal wash fluid or log10 number of PFU/g of tissue for lungs. The
lower limit of detection by this method is 0.7 log10 total PFU or approxi-
mately 1.4 log10 PFU/g of lung tissue, respectively.
Evaluation for enhanced histopathology in cotton rats. To evaluate
for enhanced histopathology attributable to vaccination following chal-
lenge, we vaccinated groups of 5 cotton rats intranasally with 105 FFU of
either kDB1 or MEM (mock treatment), or we intramuscularly injected
them with 100 l of FI-RSV (lot 100; 1:125). On day 21 p.i., we boosted
FI-RSV-vaccinated rats with a second identical vaccination. Then, on day
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42 p.i., we challenged all rats intranasally with 106 FFU (100 l) of kRSV-
A2-line19F. Six days later, we harvested the lungs and scored them for
histopathology as previously described (28). Briefly, we inflated the lungs
intratracheally with 10%neutral buffered formalin, embedded specimens
in paraffin, cut 4-m sections, and stained them with hematoxylin and
eosin. We performed blinded histopathologic scoring for four parame-
ters: peribronchiolitis (inflammatory cells, primarily lymphocytes, sur-
rounding bronchioles), perivasculitis (inflammatory cells surrounding
blood vessels), interstitial pneumonitis (increased thickness of alveolar
walls associated with inflammatory cells), and alveolitis (inflammatory
cells within alveolar spaces). Each parameter was scored separately for
each histopathologic section, with amaximum value of 4 and aminimum
of 0 (28).
Viral immunogenicity andefficacy in cotton rats.For immunogenic-
ity and efficacy studies, groups of 6 cotton rats each were inoculated i.n.
with 105 PFU of RSVA/Tracy or DB1. Prior to infection on day 0, blood
was obtained from the orbital plexus of one cotton rat in each group. On
days 28, 42, and 46 p.i., blood was obtained from all of the cotton rats. On
day 42 p.i., cotton rats were challenged i.n. with 1.35 105 PFU (100 l)
of RSVA/Tracy. Lung lavage and nasal wash specimens were obtained and
titrated 4 days postchallenge as described above.
Tests for serumneutralizing antibody (nAb) responses to RSVA/Tracy
and RSVB/18537 were performed in 96-well plates with HEp-2 cells. Se-
rum samples were heat inactivated at 56°C for 30 min, and serial 2-fold
dilutions in duplicates starting at 3 log2were performed. The nAb titerwas
defined as the serumdilution atwhich50%reduction in viral cytopathic
effect (CPE) was observed. CPE was defined as tissue destruction and was
determined visually after the wells were fixed with 10% neutral buffered
formalin and stained with crystal violet. Neutralizing antibody titers were
categorical log numbers, and the lowest detectable nAb titer was 2.5 log2.
Samples with nondetectable nAb titers were assigned a value of 2 log2.
Tests for serum nAb to the panel of RSV strains expressing mKate2
and G and F surface glycoproteins from clinical strains on days 0, 28, and
42 p.i. were performed by an FFU assay as previously described (7).
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FIG 1 Fusion activity of the Buenos Aires F protein (BAF) and its effect on attenuation in vitro and in cotton rats. (A) The consensus sequence of the BAF protein
was obtained by alignment of 5 clinical isolates from the GenBank database. Disagreements from the consensus sequence are indicated. (B) BAF fusion activity
was measured using a dual-split protein (DSP) cell-to-cell fusion assay. A representative graph from three experimental replicates shows means  SEMs of 4
replicate wells. ***, P 0.0005 using two-way ANOVA and Tukey multiple-comparison test. (C) BEAS-2B cells were infected at an MOI of 0.01 FFU/cell with
either kRSV-A2 or kRSV-A2-BAF. Growth curve data are presented as means SEMs from 3 experimental replicates titrated in triplicate. *, P 0.05; **, P
0.005; ****, P 0.00005 using two-way ANOVA and Tukey multiple-comparison test. LOD, limit of detection. (D) Groups of 5 cotton rats were infected with
either kRSV-A2-line19F or kRSV-A2-BAF. On day 4 postinfection (p.i.), lungs were harvested and viral load was measured by standard plaque assay. Each dot
represents one animal, and data represent means SDs. **, P 0.005 by two-tailed Student’s t test.
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Briefly, serum samples were heat inactivated at 56°C for 30 min. Serial
2-fold dilutions were performed in duplicate starting at 2 log2, and equal
volumes were added to 50 to 100 FFU of each of the RSV strains on the
panel. The virus and serummixtureswere incubated at 37°C for 1 h. Then,
50 l of each mixture was transferred onto subconfluent HEp-2 cell
monolayers in 96-well plates in duplicate. Plates were spinoculated at
2,095 g for 30 min at 4°C, and FFU were counted after 48 h of incuba-
tion at 37°C and 5% CO2. The 50% effective concentration (EC50) was
calculated using nonlinear regression analysis with four-parameter fitting
in GraphPad Prism version 6.0. Nondetectable nAb titers were assigned a
value of 2 log2.
Serum anti-RSV IgG antibodies on day 46 p.i. were determined by
enzyme immunoassay (EIA) against RSVA2 lysate ormock control lysate.
First, 96-well plates were coated with lysate and incubated at room tem-
perature overnight. After blocking in 5% bovine serum albumin (BSA) in
PBS containing 0.05% Tween 20 (PBST) for 1 h at room temperature,
100-l volumes of 2-fold serial dilutions of serum samples (ranging from
1:512 to 1:65,536) in PBSTwere added to appropriate wells and incubated
for 2 h at room temperature. Next, plates were washed 3 times with PBST
and incubated for 1 h at 37°C with horseradish peroxidase (HRP)-conju-
gated goat anti-mouse immunoglobulin antibody (diluted 1:1,000;
Thermo Fisher Scientific, Waltham, MA). After washing 3 times with
PBST, color was developed with an R&D Systems (Minneapolis, MN)
substrate reagent pack (stabilized hydrogen peroxide and stabilized te-
tramethylbenzidine) as indicated by the manufacturer. The enzyme-sub-
strate reaction was terminated by the addition of a sulfuric acid solution,
and absorbancewasmeasured at a wavelength of 450 nm. The cutoff value
to determine antibody titer was chosen as the mean optical density
(OD)  1 standard deviation (SD) for the lowest dilution (1:512) of se-
rum from mock-infected cotton rats. The highest serum dilution with
absorbance above the cutoff was defined as the antibody titer.
Anti-RSV IgA antibodies from cotton rat nasal washes obtained on
day 46 p.i. were similarly determined by EIA against RSV A2 or mock
stock lysates. After coating plates overnight and blocking in 5% BSA,
100-l volumes of 2-fold serial dilutions of nasal wash samples (ranging
from 1:1 to 1:128) in PBSTwere added to appropriate wells and incubated
for 2 h at room temperature. Wells were then washed with PBST and
incubated for 1 h at 37°C with HRP-conjugated goat anti-mouse IgA
(Southern Biotech, Birmingham, AL). Plates were then washed and incu-
bated with R&D Systems substrate reagents as described above. The en-
zyme-substrate reaction was terminated with a sulfuric acid solution, and
absorbance was measured at 450 nm. The cutoff to determine antibody
titer was again chosen as the mean OD 1 SD of the lowest dilution (1:1)
of nasal wash from mock-infected cotton rats. The highest nasal wash
dilution with absorbance above the cutoff was defined as the antibody
titer.
Statistical analyses. All statistical analyses were performed using
GraphPadPrism software version 6.0 (SanDiego, CA).Data are presented
as means with SDs or standard errors of the means (SEMs) as indicated
below. Student’s t test and one-way or two-way analyses of variance
(ANOVA) were used as indicated below, with Tukey’s post hoc multiple-
comparison test. For all analyses, a P value of 0.05 was considered signif-
icant.
RESULTS
Identification and characterization of a low-fusion F protein.
Wegenerated an RSV F protein consensus sequence of the Buenos
Aires (BA) clade by aligning the full-length F nucleotide sequences
from 5 BA clinical isolates in the GenBank database (http://www
.ncbi.nlm.nih.gov/GenBank/index.html) (Fig. 1A). Using a dual-
split protein (DSP) cell-to-cell fusion assay with 293T cells as pre-
viously described (23–25), we found that BAF, when expressed
alone, was poorly fusogenic compared to A2F and line19F pro-
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teins (Fig. 1B). Based on these results, we hypothesized that BAF
may confer attenuation to a vaccine candidate based on its low
fusogenicity. To test this hypothesis, we cloned BAF in place of
A2F in a bacterial artificial chromosome (BAC) construct con-
taining the antigenome of strain kRSV-A2, where k represents the
red fluorescent proteinmKate2 gene (17).We rescued this recom-
binant virus and then performedmultistep growth curve analyses
with BEAS-2B cells to compare growth of kRSV-A2-BAF to that of
kRSV-A2 in vitro. Although the two viruses replicated to similar
levels at earlier time points p.i., growth of kRSV-A2-BAF was at-
tenuated at 48, 72, and 96 h p.i. (Fig. 1C). We then measured the
effects of BAF on viral attenuation in vivo by infecting groups of 5
cotton rats intranasally with 105 FFU of either kRSV-A2-line19F
or kRSV-A2-BAF and measuring the lung viral titer 4 days later.
kRSV-A2-BAF was attenuated by 1.1 log10 PFU/g of lung (P 	
0.0054) compared to kRSV-A2-line19F in the lower respiratory
tracts of the cotton rats (Fig. 1D). Taken together, these results
demonstrated that BAF was poorly fusogenic and attenuating in
vitro and in vivo.
Design of RSV live-attenuated vaccine DB1 and expression
of viral proteins.Wenext generated anRSVLAV candidate, DB1,
by replacing the A2F gene with BAF, codon deoptimizing the
genes for the nonstructural proteins NS1 and NS2 (dNS) (7), and
deleting the small hydrophobic protein gene (SH) in an RSV-A2
backbone (Fig. 2A). Our rationale for this vaccine design was to
combine the novel low-fusion BAF protein with two attenuating ge-
neticmodifications known to preserve immunogenicity, namely, the
codon deoptimization of NS1 and NS2 and the deletion of SH pro-
tein. We generated DB1 by cloning BAF in place of A2F in the
bacterial artificial chromosome (BAC) construct containing the
antigenome of RSV-A2-dNS-SH.We similarly generated an an-
tigenomic version of DB1 containing mKate2 in the first gene
position (kDB1) and rescued these recombinant viruses (17). To
analyze viral protein levels, we performed Western blotting on
lysates from infected HEp-2 cells. The results demonstrated
that expression levels of NS1 and NS2 proteins in kDB1-in-
fected cells were less than in kRSV-A2-line19F-infected cells, as
expected, whereas F protein expression levels were equivalent
(Fig. 2B and C).
DB1 viral growth kinetics in vitro. We next characterized
kDB1 growth kinetics in vitro by performing multistep growth
curve analyses with well-differentiated primary HAE (18) and
NHBE (7) cells grown at the air-liquid interface. We employed
these two models because well-differentiated human airway epi-
thelial cells more accurately predict RSV attenuation in seronega-
tive children than immortalized cell lines or nonhuman primates
(29). In both models of well-differentiated airway epithelial cells,
kDB1 was attenuated compared to kRSV-A2, with significant dif-
ferences observed inNHBE cells on days 6 and 7 p.i. (Fig. 3A toC).
In contrast, kDB1 had growth kinetics similar to those of kRSV-
A2-line19F inVero cells, an interferon-deficient cell line approved
for vaccine production (Fig. 3D). The lack of kDB1 attenuation in
Vero cells may be in part explained by the diminished impact of
codon-deoptimized nonstructural proteins on this interferon-de-
ficient cell line. In summary, these data demonstrated that kDB1
was attenuated in primary cells in vitro but grew to sufficient levels
for rescue and production in Vero cells.
DB1attenuation andhistopathology in cotton rats.Todeter-
mine the level of DB1 attenuation in vivo in cotton rats, we in-
fected groups of 3 animals with eitherDB1 or RSVA2 (Fig. 4A and
B). On day 4 p.i., we measured viral titers in lung lavage and nasal
wash specimens. The DB1 titers were 1.7 log10 total PFU (P 	
FIG 3 kDB1 viral growth kinetics in vitro. Human airway epithelial (HAE) cells (A and B), normal human bronchial epithelial (NHBE) cells (C), or Vero cells
(D) were infected at an MOI of 6 TCID50/cell, 2.6 FFU/cell, or 0.01 FFU/cell, respectively, with either kDB1, kRSV-A2, or kRSV-A2-line19F. Virus titers were
measured at each time point by FFUassay.Growth curve data are presented asmeans SEMsof 2 or 3 experimental replicates. Representative photomicrographs
of infected HAE cells show mKate2 positivity (with red color converted to black). *, P 0.05 using two-way ANOVA and Tukey multiple-comparison test.
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0.0208) and 1.2 log10 PFU/g lung (P	 0.0022) lower than those of
RSV A2 in the lung lavage and nasal wash, respectively. These
results demonstrated that DB1was attenuated in cotton rats com-
pared to RSV A2.
To evaluate for enhanced disease attributable to vaccination
following challenge, we next vaccinated groups of 5 cotton rats
intranasally with kDB1 or a control, or intramuscularly with FI-
RSV (lot 100; 1:125). On day 21 p.i., we boosted FI-RSV-vacci-
nated rats with a second identical vaccination. On day 42 p.i., we
challenged all rats intranasally with 106 FFU of kRSV-A2-line19F.
Six days later, we harvested the lungs for histopathology and per-
formed scoring for peribronchiolitis, perivasculitis, interstitial
pneumonitis, and alveolitis (Fig. 4C to F). The average histopa-
thology scores for kDB1-vaccinated rats were statistically
equivalent to those obtained with mock treatment for all four
parameters. kDB1-vaccinated rats also had significantly lower
histopathology scores than FI-RSV-vaccinated rats for peribron-
chiolitis (P 	 0.0155) and alveolitis (P  0.0001). These results
demonstrated that kDB1 does not cause enhanced disease follow-
ing challenge in the standard cotton rat model.
DB1 immunogenicity in cotton rats. To analyze DB1 immu-
nogenicity in cotton rats, wemock infected rats or infected groups
of 6 cotton rats with 105 PFU of DB1 or RSVA/Tracy (GA1 geno-
type) and measured serum titers of nAb against RSVA/Tracy and
RSVB/18537 by microneutralization assays on days 21, 42, and 46
p.i. (Fig. 5A and B). DB1 generated nAb to both RSVA/Tracy and
RSVB/18537, and DB1 generated significantly higher serum titers
of nAb to RSVB/18537 than did RSVA/Tracy.
FIG 4 kDB1 attenuation and histopathology following challenge in cotton rats. Groups of 3 cotton rats were inoculated intranasally (i.n.) with either kRSV-A2
or kDB1. Lung lavage (A) and nasal wash (B) were performed on day 4 p.i., and viral titers were measured by plaque assay. To evaluate for vaccine-attributable
enhanced disease postchallenge, groups of 5 cotton rats were inoculated i.n. with either a control or kDB1 or intramuscularly (i.m.) with FI-RSV. Animals
vaccinated with FI-RSV also received a boost on day 21 p.i. All animals were challenged with kRSV-A2-line19F on day 46 p.i., lungs were harvested 6 days later,
and histopathology scores were determined (C). Representative hemotoxylin and eosin stains for FI-RSV-vaccinated (D), mock-vaccinated (E), and kDB1-
vaccinated (F) rats are shown. Data are presented as means SDs. *, P 0.05.
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We then pooled cotton rat serum samples from day 46 p.i. and
measured anti-RSV IgG binding antibodies via enzyme immuno-
assay (EIA) against kRSV-A2 (Fig. 5C). DB1 generated anti-RSV
IgG titers of
213, which were statistically equivalent to titers gen-
erated by RSVA/Tracy (P 	 0.4169). DB1 also generated detect-
able virus-specific IgA antibodies in cotton rat nasal washes ob-
tained on day 46 p.i. (Fig. 5D).
Breadth of neutralizing antibody responses elicited by DB1.
To further characterize the spectrumof nAb generated byDB1, we
designed a panel of chimeric RSV reporter strains expressing the
attachment (G) and F glycoproteins of a broad range of clinical
isolates in an RSV-A2 background with mKate2 in the first gene
position. The panel of viruses included glycoproteins from RSV B
strains TX11-56, NH1276, and 9320 and RSV A strains 1998/12-
21, Riyadh 91/2009, and 2-20. These strains were chosen to repre-
sent phylogenetically distant RSV strains from both subgroups
and multiple clades. We additionally generated a recombinant
virus, kRSV-A2-2-20F/G-stop, which contained a premature stop
codon in the G glycoprotein as previously described, in order to
measure the relative effects of anti-G antibodies on neutralization
(21). We also included kRSV-A2 in the panel and rescued the
recombinant viruses.
We subsequently pooled the cotton rat serum samples col-
lected on days 0, 21, and 42 p.i. and measured nAb titers at each
time point against the panel of viruses by an FFU reduction assay
(Fig. 6) (7). DB1 generated broadly neutralizing Ab responses
against both RSV A and B representative viruses that were similar
in titer to those induced by RSVA/Tracy. Antibody titers against
the chimeric clinical strains ranged fromEC50s of 2
8 to 210 per 0.05
ml and were highest against RSV B strain NH1276, followed by B
strains 9320 and TX11-56. Antibody titers were lowest against the
laboratory-adapted wild-type strain RSV-A2, which may be less
representative of currently circulating RSV clinical strains. Nota-
bly, nAb titers were higher against kRSV-A2-2-20F/G-stop than
kRSV-A2-2-20, demonstrating that the neutralization generated
by DB1 was not dependent on antibodies directed against G.
Taken together, these data demonstrated that DB1 was highly
immunogenic and generated broadly neutralizing Ab responses
against both RSV A and B strains, with the highest titers observed
against RSV B strains.
DB1 efficacy in cotton rats. To analyze vaccine efficacy (Fig.
7), we next challenged the cotton rats described above with 1.35
105 PFU of RSVA/Tracy on day 42 postvaccination and measured
RSVA/Tracy viral titers in lung lavage and nasal wash fluids by
standard plaque assay 4 days later. In lung lavage samples (Fig.
7A), vaccination with DB1 reduced viral titers after challenge by
2.7 log10 PFU/g tissue compared to titers in untreated cotton rats
(P 0.0001). In the nasal washes, DB1 reduced titers by 3.8 log10
total PFU compared to those in untreated cotton rats (P 
0.0001), which were statistically equivalent to those of RSVA/
Tracy (P	 0.3710) (Fig. 7B). DB1 was thus effective in reducing
viral titers after RSV challenge by 
99% in both the upper and
lower airways of cotton rats.
DISCUSSION
We generated an RSV live-attenuated vaccine, DB1, which was
both attenuated and highly immunogenic in cotton rats. This vac-
cine incorporated a low-fusion F protein as a novel strategy to
attenuate viral replication without compromising immunogenic-
ity. DB1 additionally incorporated two genetic modifications
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known to balance attenuation and immunogenicity, the codon
deoptimization of nonstructural proteins (7) and the deletion of
SH (13). The resultant vaccine was
10-fold attenuated in cotton
rat upper and lower airways, yet it still elicited high titers of
broadly neutralizing Ab to a diverse panel of RSV A and B recom-
binant strains. DB1 also generatedmucosal immunity in the form
of RSV-specific IgA antibodies in cotton rat nasal wash specimens.
When vaccinated animals were challenged with RSV, DB1 re-
duced challenge strain titers by
99% in both the nasal wash and
lung lavage specimens. Thus, DB1 was attenuated, highly immu-
nogenic, and efficacious at protecting against RSV challenge in
cotton rats.
To characterize the breadth of neutralization generated by
DB1, we designed a novel panel of recombinant RSV viruses ex-
pressing mKate2 and the G and F surface glycoproteins of diverse
RSV A and B clinical isolates. We found that intranasal inocula-
tion with DB1 generated broadly neutralizing Ab against our
panel of recombinant viruses, with the highest titers observed
against the RSV B strains. We additionally observed subgroup-
specific immune responses to the lab strain RSVB/18537 when
analyzed by a standard plaque reduction neutralization test
(PRNT). Notably, DB1 generated significantly higher neutraliza-
tion of RSVB/18537 than did infection with wild-type RSVA/
Tracy. Conversely, RSVA/Tracy also generated significantly
higher neutralization of RSVA/Tracy (homologous) than didDB1
on days 28 and 42 postinfection. These subgroup-specific re-
sponses must have been attributable to differences within the fu-
sion protein, as these were the principal antigenic differences be-
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tween DB1 and RSVA/Tracy. Thus, our data implicate the fusion
protein as an importantmediator of subgroup-specific immunity,
despite its highly conserved neutralizing epitopes (30). The data
also validate that RSV elicits cross-neutralizing Ab responses to
heterosubtypic viruses that are broad but variable in magnitude,
which may have implications for vaccine design (31).
The titers of nAb elicited by DB1 against our panel of recom-
binant viruses fell in the range of what is known to be protective
against lower respiratory tract infections in cotton rats. Previous
studies with cotton rats demonstrated that serum nAb titers of
1:100 conferred partial pulmonary protection, whereas titers of
1:380 completely protected against lower respiratory tract disease
(32). These results correlated with observations in human infants
2 months of age, which showed that maternally derived anti-
body titers of 1:400 offered protection against RSV bronchiolitis
and pneumonia (33). The serum nAb titers elicited by DB1 in
cotton rats to our panel of recombinant clinical viruses ranged
from 1:256 to 1:1,024 by FFU reduction assay. In comparison,
RSV LAV candidate RSV-M2-2, which is under evaluation in
clinical trials, generated nAb titers of 1:32 to 1:64 by the plaque
reduction neutralization titer necessary to reduce the number of
plaques by 60% (PRNT60) in cotton rats (34). With regard to
efficacy, DB1 was 
99% efficacious in reducing cotton rat nasal
wash and lung lavage titers postchallenge. DB1 efficacy was thus
comparable to that of palivizumab, which is dosed in humans
based on the serum trough concentration necessary to reduce the
cotton rat lung viral load by 99% (35).
With regard to attenuation, DB1 was highly attenuated in two
models of primary human airway epithelial cells, which more ac-
curately gauge levels of RSV LAV attenuation in humans than
immortalized cell lines (29). However, the vaccine was only 15-
fold attenuated in cotton rat upper airways and 45-fold attenuated
in lung lavage specimens. We suspect that this discrepancy was
observed because the dNS and SH mutations exerted minimal
effects in the cotton rat model. In fact, the BAF mutation alone
conferred a reduction in viral titer in cotton rat lower airways
(12-fold) nearly equivalent to those conferred by the combined
mutations in DB1. This is consistent with previous studies which
found that the SHmutation conferred attenuation in chimpan-
zee lower airways (13) but not in cotton rats (15). Additionally,
the dNS mutations have been characterized only in mice and pri-
mary cells (7), so their effects in cotton rats are unknown. Thus,
the applicability of the cotton rat model to approximate human
levels of attenuation with these specific mutations remains un-
clear.
In conclusion, we generated an RSV LAV DB1 that incorpo-
rated a low-fusion F protein as a novel strategy to attenuate viral
replication without compromising immunogenicity. We com-
bined this low-fusion F protein with codon-deoptimized non-
structural proteins and deleted the SHprotein in anRSV-A2 back-
bone to generate a multifaceted vaccine that balanced attenuation
and immunogenicity. DB1 also elicited broadly neutralizing anti-
bodies against a panel of RSV A and B strains and protected
against RSV challenge in cotton rats. DB1 is a promising RSV
vaccine candidate that merits further investigation.
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